Silk Road Medical upgraded to Peer Perform from Underperform at Wolfe Research

Wolfe Research upgraded Silk Road Medical to Peer Perform from Underperform without a price target. While the shares can “grind lower” in short term due to negative estimate revisions, a fresh valuation assessment “should consider takeout scenarios,” the analyst tells investors in a research note. As such, Wolfe sees a more balanced risk/reward at current share levels.